peptidase raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
3 hours, allowing enough time for base excision repair mechanisms to correct the change. However, 4-OHE2-1-N3Ade exhibits instantaneous depurination, leading to error-prone repair and the induction of mutations. Indeed, E2-3,4-Q has been shown to cause A-to-G mutations in the gene coding for H¬-ras, ras being vital to the correct regulation of the cellular response to growth factors. Though 2- and 4-OHE2 have similar redox potentials and thus similar redox cycling activity, the greater carcinogenic capacity of 4-OHE2 can be attributed to its increased reactivity with DNA. Another harmful effect of estrogen redox cycling is the production of superoxide and hydroxyl radicals. P450 reductase catalysis produces superoxide radicals, which can, in the presence of superoxide dismutase and Fe3+, form highly reactive hydroxyl radicals capable of damaging virtually all macromolecules.
Gregory L. Verdine (born June 10, 1959) is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability. Verdine is the co-inventor with Christian Schafmeister of stapled peptides, a new class of drugs that combines the versatile binding properties of monoclonal antibodies with the cell-penetrating ability of small molecules. Verdine coined the term "drugging the undruggable" to describe the unique capabilities of stapled peptides. A close analog of a stapled peptide drug invented in the Verdine Lab, sulanemadlin (ALRN-6924), is a first-in-class dual MDM2/MDMX inhibitor currently in Phase II clinical development by Aileron Therapeutics, which he co-founded in 2005. FogPharma, founded in 2016, aims to further develop stapled peptide technology for therapeutic use. He has founded numerous other drug discovery companies, including six that are listed on the NASDAQ. His companies have succeeded in developing two FDA-approved drugs, romidepsin and paritaprevir, which are, respectively, an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs), and an acylsulfonamide inhibitor that is used to treat chronic hepatitis C.
South of Centro stands the Crocetta district, considered one of the most exclusive districts of the city, because of highly rated residential buildings. At the heart of the district is the partially pedestrianised area crossed by Corso Trieste, Corso Trento and Corso Duca D'Aosta, plenty of some notable residential buildings in eclectic, neo-Gothic and Art Nouveau style. The area was built between 1903 and 1937 replacing the old parade ground, which was moved in the southern part of the city. North of this area stands the GAM (Galleria d'Arte Moderna), one of the two Museum of Modern Arts of the Turin Metro area (the second and largest one is hosted in Castello di Rivoli, a former Savoy royal castle in the suburbs). The museum stands in front a huge monument situated in the centre of the roundabout between Corso Vittorio Emanuele II and Corso Galileo Ferraris: the Monument to Vittorio Emanuele II, a king of Savoy statue situated on a 39-metres high column. Next to the museum, another significant residential building previously hosted the head office of Juventus, one of the two main Turin football clubs. West of this area, the main building of Polytechnic University of Turin stands along Corso Duca Degli Abruzzi. The 1958 building, a 122,000 m2 (1,313,197 sq ft) complex, hosts approximately 30,000 students and is considered one of the major institutes of technology of the country—mainly due to the vocation of the city for the industrialisation, pushed by the automotive sector.
Sources: en.wikipedia.org
Iphigenia Photaki (Greek: Ιφιγένεια Φωτάκη, pronounced [ifiˈʝeni.a foˈtaki]; also known after marriage as Iphigenia Vourvidou-Photaki, Greek: Ιφιγένεια Βουρβίδου-Φωτάκη; 1921–1983) was a Greek organic chemist remembered for her contributions in peptide chemical synthesis, especially in the synthesis of biologically/enzymatically active peptides. Photaki was in 1965 the fourth woman overall to be habilitated in a scientific discipline in Greece, and the second to do so in the field of Chemistry. She specialised in peptide synthesis, influenced by her mentor and doctoral advisor Leonidas Zervas, a global authority on the subject. After distinguished research in Basel, Athens, and later Cornell, Photaki eventually rose to Professor of Organic Chemistry and Head of the Laboratory of Organic Chemistry of the University of Athens.
Opium was traded from Egypt by the Phoenicians and Minoans to destinations around the Mediterranean Sea, including Greece, Carthage, and Europe. By 1100 BC, opium was cultivated on Cyprus, where surgical-quality knives were used to score the poppy pods, and opium was cultivated, traded, and smoked. Opium was also mentioned after the Persian conquest of Assyria and Babylonian lands in the 6th century BC.
16 December – The UK government orders an independent review into foreign financial interference in UK politics in response to the case of Nathan Gill, the former leader of Reform UK in Wales. The Employment Rights Bill passes its final vote in the House of Lords and will receive Royal ascent before Christmas. It is announced that former Chancellor George Osborne is to join OpenAI. 17 December – Labour grants six local authorities in and around London the power to raise larger council tax increases after reducing their share of government funding. Starmer urges Russian oligarch Roman Abramovich to honour the pledge he made to donate the £2.5bn he made from the sale of Chelsea F.C. in 2022 to victims of the Ukraine War or he will face legal proceedings. Andrea Egan is elected as general secretary of Unison, and will succeed Christina McAnea in January. Former Labour mayor Jamie Driscoll joins the Green Party. Independent MP Zarah Sultana begins a protest outside HMP Bronzefield in Surrey, where remand prisoner, who had spent over a year in prison awaiting trial, and Palestine Action member Qesser Zuhrah is on hunger strike. The protest demanded an ambulance be brought to the prison, where Zuhrar has been on hunger strike for 46 days. She was later transferred to hospital. 18 December – Christian Turner is named as the UK's new ambassador to the United States, replacing Peter Mandelson. It is announced that Nigel Farage will not face an investigation into claims Reform overspent during his 2024 election campaign.
=== Brain === Broad generalizations are often made in popular psychology about certain brain functions being lateralized, or more predominant in one hemisphere than the other. These claims are often inaccurate or overstated. The human brain, particularly the prefrontal cortex, does not reach "full maturity" or "full development" at any particular age (e.g. 16, 18, 21, 25, 30). Changes in structure and myelination of gray matter are recorded to continue with relative consistency all throughout life including until death. Different mental abilities peak earlier or later in life. Humans do not generate all of the brain cells they will ever have by the age of two years. Although this belief was held by medical experts until 1998, it is now understood that new neurons can be created after infancy in some parts of the brain into late adulthood. People do not use only 10% of their brains. While it is true that a small minority of neurons in the brain are actively firing at any one time, a healthy human will normally use most of their brain over the course of a day, and the inactive neurons are important as well. The idea that activating 100% of the brain would allow someone to achieve their maximum potential and/or gain various psychic abilities is common in folklore and fiction, but doing so in real life would likely result in a fatal seizure. This misconception was attributed to late 19th century leading thinker William James, who apparently used the expression only metaphorically.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.